Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 20, 2019updated 23 Dec 2019 10:23am

BGU develops new AI platform to track neurodegenerative disorders

BGN Technologies, the technology transfer company of Israel-based Ben-Gurion University (BGU), has unveiled a new artificial intelligence (AI) platform to monitor and predict the progression of neurodegenerative diseases.

BGN Technologies, the technology transfer company of Israel-based Ben-Gurion University (BGU), has unveiled a new artificial intelligence (AI) platform to monitor and predict the progression of neurodegenerative diseases.

Developed by professor Boaz Lerner at the BGU’s Department of Industrial Engineering and Management, the platform is expected to enable the identification of markers for personalised patient care and improved drug development.

Initially, the platform will be used to track amyotrophic lateral sclerosis (ALS), with plans to expand its application to other neurodegenerative conditions, including Parkinson’s and Alzheimer’s diseases.

“The platform will utilise machine learning and data mining algorithms to analyse demographic and clinical data in order to generate models for predicting the rate and pattern of ALS progression.”

Complicated research and drug development for ALS is attributed to the heterogeneity of the patient population that results in variability in onset symptoms, disease progression rate and pattern, and survival.

BGN Technologies said that the new platform will improve care and quality of life for ALS patients through reliable stratification to homogenous sub-groups, and personalised prediction of disease progression rate and pattern.

The platform will utilise machine learning and data mining algorithms to analyse demographic and clinical data in order to generate models for predicting the rate and pattern of ALS progression.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

These models can also be used to identify factors required for the prediction and stratify homogenous sub-groups from the heterogeneous ALS population.

In addition, the platform is expected to improve clinical trials design and the clinical evaluation of treatment by identifying markers of different sub-populations for which treatment is beneficial, in turn enhancing success rates of studies.

Lerner said: “The novel platform, which uses machine learning algorithms, will enable not only accurate prediction of disease progression, a crucial ingredient for better clinical trials, but also identification of interrelationships between demographics and measurable factors from physical examinations and patient functionality that will advance clinical research of this devastating condition.”

BGN Technologies intends to use recent funds from the Israel Innovation Authority to develop a system that will enable implementation of the new technology on personal computers (PCs), the cloud and cellular applications.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU